Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia

ABSTRACTPersons with Fanconi anemia (FA) are at risk for human papillomavirus (HPV)-associated cancers; however, their natural HPV exposure and infection rates are unknown as is the adequacy with which they mount antibodies to HPV vaccination. This study aimed to determine, in 62 persons with FA, the seroprevalence of skin and mucosal HPV types, the seroprevalence in individuals self-reporting a history of HPV vaccination, and the factors associated with HPV seropositivity. A bead Luminex assay was used to determine seropositivity for HPV1, -2, and -4 (low-risk skin), -6 and -11 (low-risk mucosal, included in one HPV vaccine), -16 and -18 (high-risk mucosal, included in both HPV vaccines), and -52 and -58 (high-risk mucosal). Health- and behavior-related questionnaires were completed. Type-specific seroprevalence estimates and participant characteristics associated with seroprevalence were calculated; 48% reported HPV vaccination. Type-specific seropositivity in unvaccinated persons ranged from 7 to 21% for skin HPV types and 7 to 38% for mucosal HPV types. Among the unvaccinated participants, adults versus children demonstrated increased HPV1, -6, -16, and -58 seroprevalence of 45% versus 6%, 64% versus 22%, 64% versus 17%, and 36% versus 0%, respectively (allP< 0.05). The vaccinated participants versus the nonvaccinated participants demonstrated increased seroprevalence of HPV6, -11, -16, and -18 of 92% versus 38%, 92% versus 24%, 96% versus 34%, and 75% versus 7%, respectively (allP< 0.0001). Our data demonstrate that the unvaccinated participants had serologic evidence of prior skin and mucosal HPV infections and that seroprevalence increased among adults; in self-reported vaccinees, seroprevalence of HPV vaccine types was 75 to 96%.

Download Full-text

HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe

Acta Facultatis Medicae Naissensis ◽

10.2478/afmnai-2018-0001 ◽

2018 ◽

Vol 35 (1) ◽

pp. 5-16

Author(s):

Holger Stark ◽

Aleksandra Živković

Keyword(s):

Cervical Cancer ◽

High Risk ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Low Risk ◽

Vaccination Rates ◽

Protection Efficacy ◽

Efficient Protection ◽

Hpv Types ◽

High Risk Hpv

Summary The identification of the high-risk human papilloma viruses (HPVs) as a cause of cervical cancer offered the possibility for the development of a HPV vaccine. Twenty years after this identification of the HPV types, the first HPV vaccine came to the market. There are three HPV vaccines today on the market, all containing the virus-like particles (VLPs) of the HPV types 16 and 18, which are considered to cause 77 % of all cancers caused by HPVs. In addition, two of the vaccines contain two low-risk HPV types (6 and 11)-quadrivalent or the same as low-risk types and additional high-risk HPV types (31, 32, 45, 52, 58)-nonavalent vaccines. The cervical cancer protection efficacy of the vaccines is very high, around 100%. The VLPs of the 6- and 11-type offer efficient protection against genital warts. Unfortunately, the implementation of the vaccination is actually not so high despite all scientific and medical facts, but their rates in Europe are steadily increasing reaching about 90% in one country after another. In Serbia, all of the three vaccines are on the market but are highly underused. Actually, there is no national program and the Serbian vaccination rates are very low. High vaccination rates in Serbia need to be achieved as a goal of prevention of cervical cancer.

Download Full-text

Additional Human Papillomavirus Types Detected by the Hybrid Capture Tube Test among Samples from Women with Cytological and Colposcopical Atypia

Journal of Clinical Microbiology ◽

10.1128/jcm.38.1.408-411.2000 ◽

2000 ◽

Vol 38 (1) ◽

pp. 408-411

Author(s):

József Kónya ◽

György Veress ◽

Attila Juhász ◽

Krisztina Szarka ◽

Tamás Sápy ◽

...

Keyword(s):

Human Papillomavirus ◽

High Risk ◽

Fragment Length Polymorphism ◽

Low Risk ◽

Double Positive ◽

Detection Range ◽

Hybrid Capture ◽

Pcr Rflp ◽

Hpv Types ◽

High Risk Hpv

ABSTRACT The type specificity of the human papillomavirus (HPV) Hybrid Capture Tube (HCT) test was evaluated by using typing with PCR (MY09-MY11)-restriction fragment length polymorphism (RFLP) and sequencing. All samples HCT test positive for only low-risk HPV ( n = 15) or only high-risk HPV ( n = 102) were confirmed, whereas 9 of 12 HCT test double-positive samples contained only high-risk HPV types as determined by PCR-RFLP. Several high-risk HPV types (HPV-53, -58, -62, -66, -CP8304, and -MM4) not included in the HCT test were indeed detected, indicating a broader detection range with retained distinction between low-risk and high-risk HPV types.

Download Full-text

Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls

The Journal of Infectious Diseases ◽

10.1093/infdis/jiaa709 ◽

2020 ◽

Author(s):

Ida Laake ◽

Berit Feiring ◽

Christine Monceyron Jonassen ◽

John H-O Pettersson ◽

Torstein Gjølgali Frengen ◽

...

Keyword(s):

Logistic Regression ◽

Human Papillomavirus ◽

High Risk ◽

Hpv Vaccination ◽

Hpv Infection ◽

Concurrent Infection ◽

Birth Cohorts ◽

Mixed Effect ◽

Hpv Genotypes ◽

Hpv Types

Abstract Background Whether type-specific human papillomavirus (HPV) infection influences the risk of acquiring infections with other HPV types is unclear. We studied concurrent HPV infections in 17-year-old girls from 2 birth cohorts; the first vaccine-eligible cohort in Norway and a prevaccination cohort. Methods Urine samples were collected and tested for 37 HPV genotypes. This study was restricted to unvaccinated girls from the prevaccination cohort (n = 5245) and vaccinated girls from the vaccine-eligible cohort (n = 4904). Risk of HPV infection was modelled using mixed-effect logistic regression. Expected frequencies of concurrent infection with each pairwise combination of the vaccine types and high-risk types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) were compared to observed frequencies. Results Infection with multiple HPV types was more common among unvaccinated girls than vaccinated girls (9.2% vs 3.7%). HPV33 and HPV51 was the only HPV pair that was detected together more often than expected among both unvaccinated (P = .002) and vaccinated girls (P < .001). No HPV pairs were observed significantly less often than expected. Conclusions HPV33 and HPV51 tended to be involved in coinfection among both unvaccinated and vaccinated girls. The introduction of HPV vaccination does not seem to have had an effect on the tendency of specific HPV types to cluster together.

Download Full-text

Cellular Changes Induced by Low-Risk Human Papillomavirus Type 11 in Keratinocytes That Stably Maintain Viral Episomes

Journal of Virology ◽

10.1128/jvi.75.16.7564-7571.2001 ◽

2001 ◽

Vol 75 (16) ◽

pp. 7564-7571 ◽

Cited By ~ 43

Author(s):

Jennifer T. Thomas ◽

Stephen T. Oh ◽

Scott S. Terhune ◽

Laimonis A. Laimins

Keyword(s):

Human Papillomavirus ◽

Life Cycle ◽

High Risk ◽

Life Cycles ◽

Low Risk ◽

Global Changes ◽

Culture Methods ◽

Transfected Cells ◽

Hpv Types ◽

High Risk Hpv

ABSTRACT Infections by low-risk papillomavirus types, such as human papillomavirus (HPV) type 6 (HPV-6) and HPV-11, induce benign genital warts that rarely progress to malignancy. In contrast, lesions induced by high-risk HPV types have the potential to progress to cancer. Considerable information is available concerning the pathogenesis of high-risk HPV types, but little is known about the life cycle of low-risk HPV types. Although functionally distinct, both high- and low-risk virus types infect keratinocytes and induce virion production upon differentiation. This information suggests that they may share common mechanisms for regulating their productive life cycles. Using tissue culture methods developed to study high-risk HPV types, we examined the ability of HPV-11 to be stably maintained as episomes following transfection of normal human keratinocytes with cloned viral DNA. HPV-11 genomes were found to be maintained in keratinocytes for extended passages in cultures in 14 independent experiments involving transfection of cloned HPV-11 DNA. Interestingly, the HPV-11-positive cells exhibited an extended life span that averaged approximately twofold longer than that of control neomycin-transfected cells. In organotypic cultures, HPV-11-positive cells exhibited altered differentiation patterns, but the extent of disruption was less severe than that seen with high-risk HPV types. In addition, the amplification of HPV-11 DNA, as well as the induction of several viral messages, was observed following differentiation of transfected cells in semisolid media. To determine whether global changes in cellular gene expression induced by HPV-11 were similar to those observed with high-risk HPV-31 (Y. E. Chang and L. A. Laimins, J. Virol. 74:4174–4182, 2000), microarray analysis of 7,075 expressed sequences was performed. A spectrum of cellular genes different from that previously reported for HPV-31 was found to be activated or repressed by HPV-11. The expression of only a small set of genes was similarly altered by both high- and low-risk HPV types. This result suggests that different classes of HPVs have distinct effects on global cellular transcription patterns during infection. The methods described allow for a genetic analysis of HPV-11 in the context of its differentiation-dependent life cycle.

Download Full-text

Human papillomavirus infection prevalence in female university students in Novi Sad, Serbia

Srpski arhiv za celokupno lekarstvo ◽

10.2298/sarh1606300k ◽

2016 ◽

Vol 144 (5-6) ◽

pp. 300-306 ◽

Cited By ~ 1

Author(s):

Gordana Kovacevic ◽

Aleksandra Jovanovic-Galovic ◽

Vladimir Petrovic ◽

Zeljka Vinarz ◽

Gordana Marinkovic ◽

...

Keyword(s):

Human Papillomavirus ◽

High Risk ◽

University Students ◽

Statistical Significance ◽

Hpv Infection ◽

Low Risk ◽

Infection Prevalence ◽

Gynecological Examination ◽

Hpv Types ◽

Novi Sad

Introduction. Cervical cancer, attributed to human papillomavirus (HPV) infection, represents the fourth most common and lethal cancer in Serbian women, and the second most common cancer in women aged 15-44. Objective. The aim of the study was to determine the presence of high-risk and low-risk HPV types in population of unvaccinated female university students in Novi Sad, Serbia, and to evaluate possible risk factors for HPV infection. Methods. Sample consisted of 250 young women (19-26 years of age) attending outpatient clinics for screening gynecological examination. All participants in the study completed a specially designed anonymous questionnaire. For the detection of HPV DNA, two commercial kits - High Risk HPV Real-TM and Low Risk HPV 6/11 Real-TM (Sacace Biotechnologies, Como, Italy) were used. Thirty positive samples were retested by GenoFlow HPV Array Test (DiagCor Bioscience Incorporation Limited, Hong Kong, China). Results. The overall prevalence rate of HPV was 61.6%. The most common HPV types in the present study were as follows: HPV 16, 31, 51, 52, and 18. Female students with only one sexual partner had significantly lower chance of having HPV infection. Other variables describing lifestyle did not show statistical significance. Conclusion. The present paper provides data on the prevalence of high- and low-risk HPV genotypes among university students in Novi Sad. Obtained results indicate the need for educational activities on sexually transmitted infections, including HPV, together with promotion of healthy lifestyles. According to our results, bivalent and quadrivalent prophylactic vaccines have the potential to prevent over 50% of infections. Percentage of protection with a second-generation prophylactic nonavalent vaccine would be more than 80%.

Download Full-text

Human papillomavirus prevalence to age 60 years among Australian women prevaccination

Sexual Health ◽

10.1071/sh15035 ◽

2015 ◽

Vol 12 (4) ◽

pp. 353 ◽

Cited By ~ 4

Author(s):

Julia M. L. Brotherton ◽

John R. Condon ◽

Peter B. McIntyre ◽

Sepehr N. Tabrizi ◽

Michael Malloy ◽

...

Keyword(s):

Human Papillomavirus ◽

High Risk ◽

Sexual Debut ◽

Cervical Screening ◽

Hpv Vaccination ◽

Normal Cytology ◽

Screening Programs ◽

Hpv Types ◽

High Risk Hpv ◽

Second Peak

Background The prevalence of human papillomavirus (HPV) at the cervix varies with age, peaking following sexual debut and declining thereafter in most populations. In some populations, a second peak is observed. Here we describe the prevalence of HPV at the cervix among Australian women before the commencement of the HPV vaccination program. Methods: Women aged 15 to 60 years attending health services for cervical screening between 2005 and 2008 were invited to participate. Liquid based cervical specimens were tested for 37 types of HPV using linear array. The percentage and 95% confidence interval of women with any type of HPV, any of 13 high risk HPV types, and with vaccine-preventable HPV types (types 6, 11, 16 and 18) were estimated in 5-year age bands. Results: Among 1929 women aged 15–60 years, HPV prevalence peaked at 64% at age 15–20 years, then declined gradually to 12% at age 41–45 years, whereafter it rose to 19% in women 51–55 years then returned to 14% in 56–60 year olds. Prevalence curves were similar for high-risk HPV types and vaccine-targeted HPV types 6, 11, 16 and 18 and when results were restricted to women with only normal cytology. Conclusions: The shape of the prevalence curve we observed is similar to those from other Western populations. Variation in prevalence curves is likely due to differences in sexual behaviour between populations and over time, reactivation of HPV during perimenopause, and possibly the presence of cervical screening programs. These data are the first such data from the Oceania region.

Download Full-text

Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines

Journal of Virology ◽

10.1128/jvi.01088-09 ◽

2009 ◽

Vol 83 (19) ◽

pp. 10085-10095 ◽

Cited By ~ 78

Author(s):

Christina Schellenbacher ◽

Richard Roden ◽

Reinhard Kirnbauer

Keyword(s):

Human Papillomavirus ◽

High Risk ◽

Capsid Protein ◽

Broad Spectrum ◽

Neutralizing Antibodies ◽

Low Risk ◽

Virus Like Particles ◽

Monophosphoryl Lipid A ◽

Hpv Types ◽

Cross Neutralization

ABSTRACT The amino (N) terminus of the human papillomavirus (HPV) minor capsid protein L2 can induce low-titer, cross-neutralizing antibodies. The aim of this study was to improve immunogenicity of L2 peptides by surface display on highly ordered, self-assembled virus-like particles (VLP) of major capsid protein L1, and to more completely characterize neutralization epitopes of L2. Overlapping peptides comprising amino acids (aa) 2 to 22 (hereafter, chimera or peptide 2-22), 13 to 107, 18 to 31, 17 to 36, 35 to 75, 75 to 112, 115 to 154, 149 to 175, and 172 to 200 of HPV type 16 (HPV16) L2 were genetically engineered into the DE surface loop of bovine papillomavirus type 1 L1 VLP. Except for chimeras 35-75 and 13-107, recombinant fusion proteins assembled into VLP. Vaccination of rabbits with Freund's adjuvanted native VLP induced higher L2-specific antibody titers than vaccination with corresponding sodium dodecyl sulfate-denatured proteins. Immune sera to epitopes within residues 13 to 154 neutralized HPV16 in pseudovirion neutralization assays, whereas chimera 17-36 induced additional cross-neutralization to divergent high-risk HPV18, -31, -45, -52, and -58; low-risk HPV11; and beta-type HPV5 (titers of 50 to 10,000). Aluminum hydroxide-monophosphoryl lipid A (Alum-MPL)-adjuvanted VLP induced similar patterns of neutralization in both rabbits and mice, albeit with 100-fold-lower titers than Freund's adjuvant. Importantly, Alum-MPL-adjuvanted immunization with chimeric HPV16L1-HPV16L2 (peptide 17-36) VLP induced neutralization or cross-neutralization of HPV16, -18, -31, -45, -52, and -58; HPV6 and -11; and HPV5 (titers of 50 to 100,000). Immunization with HPV16 L1-HPV16 L2 (chimera 17-36) VLP in adjuvant applicable for human use induces broad-spectrum neutralizing antibodies against HPV types evolutionarily divergent to HPV16 and thus may protect against infection with mucosal high-risk, low-risk, and beta HPV types and associated disease.

Download Full-text

Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia

Cancers ◽

10.3390/cancers13061368 ◽

2021 ◽

Vol 13 (6) ◽

pp. 1368

Author(s):

Sharon L. Sauter ◽

Xue Zhang ◽

Lindsey Romick-Rosendale ◽

Susanne I. Wells ◽

Kasiani C. Myers ◽

...

Keyword(s):

Risk Factors ◽

Human Papillomavirus ◽

Fanconi Anemia ◽

Hpv Vaccination ◽

Serum Samples ◽

Serological Studies ◽

Oral Hpv ◽

Hpv Types ◽

Family Advocacy

High-risk human papillomavirus (HPV) is prevalent and known to cause 5% of all cancers worldwide. The rare, cancer prone Fanconi anemia (FA) population is characterized by a predisposition to both head and neck squamous cell carcinomas and gynecological cancers, but the role of HPV in these cancers remains unclear. Prompted by a patient-family advocacy organization, oral HPV and HPV serological studies were simultaneously undertaken. Oral DNA samples from 201 individuals with FA, 303 unaffected family members, and 107 unrelated controls were tested for 37 HPV types. Serum samples from 115 individuals with FA and 55 unrelated controls were tested for antibodies against 9 HPV types. Oral HPV prevalence was higher for individuals with FA (20%) versus their parents (13%; p = 0.07), siblings (8%, p = 0.01), and unrelated controls (6%, p ≤ 0.001). A FA diagnosis increased HPV positivity 4.84-fold (95% CI: 1.96–11.93) in adjusted models compared to unrelated controls. Common risk factors associated with HPV in the general population did not predict oral positivity in FA, unlike unrelated controls. Seropositivity and anti-HPV titers did not significantly differ in FA versus unrelated controls regardless of HPV vaccination status. We conclude that individuals with FA are uniquely susceptible to oral HPV independent of conventional risk factors.

Download Full-text

Effectiveness of HPV vaccination in preventing recurrent cervical intraepithelial neoplasia after excisional treatment

Voprosy ginekologii akušerstva i perinatologii ◽

10.20953/1726-1678-2021-4-38-44 ◽

2021 ◽

Vol 20 (4) ◽

pp. 38-44

Author(s):

N.V. Zarochentseva ◽

◽

L.K. Dzhidzhikhiya ◽

V.N. Nabieva ◽

◽

...

Keyword(s):

Human Papillomavirus ◽

Cervical Intraepithelial Neoplasia ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Intraepithelial Neoplasia ◽

Quadrivalent Vaccine ◽

Treatment Methods ◽

Hpv Types ◽

Residual Lesions

Objective. To evaluate the results of surgical treatment of patients with cervical intraepithelial neoplasia (CIN) using excisional techniques and post-operative implementation of a quadrivalent human papillomavirus (HPV) vaccine. Patients and methods. Excisional treatment methods were used in 150 patients with CIN: 60 patients received a quadrivalent vaccine against HPV (type 6, 11, 16, 18) after surgery and 90 patients were not vaccinated. Post-operative examination was performed 3, 6, 12, 18, and 24 months after surgery and annually thereafter. Detection of CIN within 12 months after surgery was considered as a residual lesion, and more than 12 months after surgery – as a recurrence of the disease. Results. The post-operative follow-up periods for the vaccinated patients ranged from 6 to 93 months (median: 34 months), without vaccination: 6 to 202 months (median: 54 months). Residual lesions were not revealed among vaccinated patients and were revealed in 13.3% (12/90) of unvaccinated patients (p = 0.039). Recurrence of CIN among patients with follow-up for 12 months or more was noted in 3.3% (2/60) of vaccinated patients and 34.6% (27/78) of unvaccinated patients (p = 0.016). Conclusion. Vaccination against HPV (types 6, 11, 16, 18) after excisional treatment methods has significantly (approximately ten-fold) reduced the probability of CIN recurrence and may be considered as an effective approach to improve the results of treating patients with CIN. Key words: human papillomavirus, cervical intraepithelial neoplasia, vaccine, excisional treatment methods

Download Full-text

High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine

Sexually Transmitted Infections ◽

10.1136/sextrans-2017-053109 ◽

2017 ◽

Vol 94 (4) ◽

pp. 263-267 ◽

Cited By ~ 5

Author(s):

Desiree J Hooi ◽

Birgit I Lissenberg-Witte ◽

Maurits N C de Koning ◽

Herbert M Pinedo ◽

Gemma G Kenter ◽

...

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

High Risk ◽

Hpv Vaccine ◽

Precancerous Lesions ◽

Cervical Cancers ◽

Hpv Genotypes ◽

Hpv Types ◽

Dna Enzyme Immunoassay ◽

High Risk Hpv

BackgroundCuraçao is a Dutch-Caribbean Island located in a high-risk area for cervical cancer.Prior to introduction of a prophylactic human papillomavirus (HPV) vaccine, knowledge of the prevalence of high-risk HPV vaccine genotypes (HPV16, 18, 31, 33, 45, 52 and 58) in cervical (pre)cancer is required.ObjectiveTo investigate the prevalence of HPV genotypes in invasive cervical cancers (ICC) and cervical intraepithelial neoplasia (CIN) grade 1, 2 and 3 in Curaçao.MethodsParaffin-embedded blocks of 104 cervical cancers (89 squamous, 15 adenocarcinoma), 41 CIN3, 39 CIN2 and 40 CIN1 lesions were analysed for the presence of HPV. Sections were stained by H&E for histopathological evaluation, and DNA was extracted using proteinase K. HPV genotypes were detected using Short PCR Fragment (SPF10) PCR DNA enzyme immunoassay and a Line Probe Assay (LiPA25) .ResultsHPV was found in 92 (88.5%) ICC; 87 (94.6%) had a single HPV infection and 86 (93.5%) were high-risk human papillomavirus (hrHPV)-type positive.The three most common HPV types in ICC were 16 (38.5%), 18 (13.5%) and 45 (6.7%), covering 58.7%.HrHPV vaccine genotypes 16, 18, 31, 35, 45, 52 and 58 were responsible for 73.1% of ICC. For precancerous lesions, the HPV attribution was 85.4% for CIN3, 66.7% for CIN2% and 42.5% for CIN1.ConclusionsOur study, the largest in the Caribbean region in (pre)cancer, shows that the prevalence of HPV-type 16 and 18 in cervical cancer is lower compared with the world population but no differences in prevalence of these two HPV types are seen in precancerous lesions.When considering HPV vaccination in Curaçao, the relatively high contribution of non-HPV 16/18 genotypes in ICC should be taken into account.

Download Full-text